Hooman Kamel, M.D., M.S.
Hooman Kamel, M.D., M.S.
Locations and Appointments
Please contact the doctor's office to verify that your insurance is accepted.
*Indicates this doctor is no longer accepting new patients with this insurance plan.
- HMO
- Medicare
- PPO
- EPO/POS
- CHP
- Blue Access
- Blue Connection
- EPO
- HMO
- Mediblue (Senior)
- PPO
- CBP
- Medicaid
- Medicare
- Freedom
- Liberty
- Medicare Advantage
- Metro/Core/Charter
- Community Plan
- Medicare
- HMO
- Medicare
About Hooman Kamel, M.D., M.S.
Dr. Kamel is the Vice Chair for Research and Chief of Neurocritical Care in the Department of Neurology at Â鶹¸ßÇå. He is also the Director of the Clinical and Translational Neuroscience Unit in the Feil Family Brain and Mind Research Institute and the Department of Neurology at Â鶹¸ßÇå. His research focuses on the relationship between cardiac disease and stroke. He has published several studies showing that atrial cardiopathy may be a previously unrecognized risk factor for stroke. He is a principal investigator and protocol lead for the NIH-funded ARCADIA trial, which is testing antithrombotic strategies in patients with stroke and atrial cardiopathy. He is also a principal investigator of the NIH-funded ASPIRE trial, which is testing antithrombotic strategies in patients with atrial fibrillation and intracerebral hemorrhage. He has published over 300 scientific publications, including in leading journals such as NEJM and JAMA.
Dr. Kamel attended college at Harvard and medical school at Columbia, then trained as a neurology resident and neurocritical care fellow at the University of California, San Francisco before joining Â鶹¸ßÇå in 2011. He has a masters degree in data science from the Columbia University Data Science Institute and is spearheading efforts to establish neurocritical care research registries using existing electronic medical records. Dr. Kamel has led multiple studies using novel “big data” approaches on a variety of topics including cardiovascular complications of pregnancy, liver disease, and sepsis.
Dr. Kamel is a member of the international AF-SCREEN collaboration and the American Neurological Association Scientific Program Advisory Committee. He serves as the Deputy Editor of JAMA Neurology and an editorial board member of Stroke. His academic contributions have been recognized by the Michael S. Pessin Stroke Leadership Prize from the American Academy of Neurology and the Robert G. Siekert New Investigator Award in Stroke and the Joseph A. Vita Award from the American Heart Association.
2000 Undergraduate Leadership Scroll, Harvard
2005 Helen M. Sciarra Prize for Outstanding Performance in Neurology, Columbia
2009 Outstanding Research Award, UCSF Clinical and Translational Science Institute
2010 Innovation Fund Award, UCSF Academy of Medical Educators
2011 Loan Repayment Program Award, National Institutes of Health
2012 Cornell Neurology Residents’ Annual Award for Faculty Teaching
2013 American Heart Association Scientist Development Grant
2013 NIH/NINDS K23 Career Development Award
2013 Weill Cornell Healthcare Leadership Fellow
2014 Presidential Citation, Neurocritical Care Society
2014 Michael S. Pessin Stroke Leadership Prize, American Academy of Neurology
2016 Robert G. Siekert New Investigator Award, American Heart Association
2020 Joseph A. Vita Award, American Heart Association
-
M.S.Columbia University2020
-
M.D.Columbia University College of Physicians and Surgeons2005
-
B.A.Harvard College2000
-
Helen and Albert Moon Professor of NeurologyWeill Cornell Medical College, Cornell University
-
Professor of NeurologyWeill Cornell Medical College, Cornell University
-
Professor of NeuroscienceWeill Cornell Medical College, Cornell University
External Relationships
Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.